[
  {
    "drug": "Azer-cel",
    "indication": "DLBCL",
    "phase": "Phase 1b",
    "status": "Completed",
    "start_date": "2022-06-01",
    "end_date": "2023-09-15",
    "results": "Positive efficacy signals with 60% improved response rate",
    "next_milestone": "Phase 2/3 initiation in Q3 2025"
  },
  {
    "drug": "Azer-cel",
    "indication": "DLBCL",
    "phase": "Phase 2/3",
    "status": "Planned",
    "start_date": "2025-08-01",
    "end_date": "2027-12-31",
    "results": "Pending",
    "next_milestone": "Potential BLA submission in 2028"
  },
  {
    "drug": "HER-Vaxx",
    "indication": "Gastric Cancer",
    "phase": "Phase 2",
    "status": "Completed",
    "start_date": "2021-03-15",
    "end_date": "2023-05-30",
    "results": "Median OS of 14.2 months vs. 8.8 months for standard of care",
    "next_milestone": "Partnership discussions for Phase 3"
  },
  {
    "drug": "HER-Vaxx",
    "indication": "Gastric Cancer",
    "phase": "Phase 3",
    "status": "Planned",
    "start_date": "2026-01-15",
    "end_date": "2028-06-30",
    "results": "Pending",
    "next_milestone": "Potential approval in 2029"
  },
  {
    "drug": "CF33/VAXINIA",
    "indication": "Bile Tract Cancer",
    "phase": "Phase 1",
    "status": "Ongoing",
    "start_date": "2023-09-01",
    "end_date": "2025-12-15",
    "results": "Interim data expected Q4 2025",
    "next_milestone": "Phase 2 decision in Q1 2026"
  },
  {
    "drug": "CF33/VAXINIA",
    "indication": "Solid Tumors",
    "phase": "Phase 1",
    "status": "Ongoing",
    "start_date": "2023-04-15",
    "end_date": "2026-02-28",
    "results": "Preliminary data shows tumor shrinkage in 3/10 patients",
    "next_milestone": "Completion of dose escalation in Q2 2026"
  },
  {
    "drug": "PD1-Vaxx",
    "indication": "NSCLC",
    "phase": "Phase 1",
    "status": "Ongoing",
    "start_date": "2022-11-01",
    "end_date": "2024-12-31",
    "results": "85% antibody response rate with T-cell activation",
    "next_milestone": "Phase 1b expansion cohort data in Q1 2026"
  },
  {
    "drug": "PD1-Vaxx",
    "indication": "NSCLC",
    "phase": "Phase 1b",
    "status": "Planned",
    "start_date": "2025-01-15",
    "end_date": "2026-03-31",
    "results": "Pending",
    "next_milestone": "Phase 2 decision in Q2 2026"
  },
  {
    "drug": "NeoPOLEM",
    "indication": "MSI-high CRC",
    "phase": "Phase 2",
    "status": "Ongoing",
    "start_date": "2023-07-01",
    "end_date": "2025-09-30",
    "results": "40% objective response rate in first 15 patients",
    "next_milestone": "Interim data in Q3 2025"
  }
]